Macomics utilizes its proprietary ENIGMAC™ platform to identify and validate therapeutic targets by analyzing human disease-specific macrophage biology. The company focuses on developing novel therapeutics that modulate macrophage activity in cancer and other diseases where existing treatments are ineffective.
Funding
$9.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current therapeutic options are limited or ineffective for many diseases where macrophages play a central role in disease etiology, including specific tumor subtypes, neurological conditions, and fibrotic and inflammatory diseases. A deeper understanding of macrophage biology is needed to develop more effective treatments.
Solution
Macomics is a drug discovery company applying its understanding of macrophage biology to develop novel therapeutics that directly modulate macrophage activity. The company's ENIGMAC™ platform enables the creation of genetic models of disease to uncover potential drug targets. Macomics is building a pipeline of therapeutic candidates, including antibody and small molecule programs, focused on diseases where macrophages play a central role in disease progression and patient outcomes.
Target Audience
Macomics' primary customers are pharmaceutical companies seeking novel therapeutic targets and drug candidates in areas where macrophages play a key role in disease.
Features
- ENIGMAC™ platform for target discovery and validation
- Focus on genetically-evidenced, disease-specific macrophage biology
- Portfolio of antibody and small molecule programs
- Modality-agnostic approach to therapeutic development
- Programs targeting specific tumor subtypes, neurological conditions, and fibrotic and inflammatory diseases